The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
VJVirtual | GPS and NPS: novel immunotherapeutics from SELLAS
Angelos M. Stergiou, MD, ScD, SELLAS Life Sciences Group, New York, NY, discusses the origins of SELLAS Life Sciences, a late-stage pharmaceutical company developing novel cancer immunotherapeutics across a variety of cancer indications, focusing of galinpepimut-S (GPS), an immunotherapeutic targeting the Wilms Tumor 1 (WT1) protein, as well as nelipepimut-S, a HER2-directed cancer immunotherapy. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).
